This article is more than 5 years old. Information may no longer be current.

FDA acts on CAR T-cell therapy, other top stories in hematology/oncology

The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma — an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.

Read a summary of the FDA’s decision and all of last’s week’s top stories in hematology/oncology.

FDA grants CAR T-cell therapy regenerative medicine advanced therapy designation for multiple myeloma

The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma. Read more.

National Comprehensive Cancer Network's off-label cancer treatment recommendations ‘constitute a problem’

HemOnc Today spoke with Vinay K. Prasad, MD, MPH, about recommendations from the National Comprehensive Cancer Network for off-label cancer therapies, which he says are based on little or no evidence. Read more.

Study suggests National Comprehensive Cancer Network off-label recommendations valid based on available evidence

HemOnc Today also spoke with Razelle Kurzrock, MD, who contends that recommendations from the National Comprehensive Cancer Network for off-label cancer therapies are valid. Read more.

Studies show oncologists can adapt quickly to new evidence

As emerging cancer treatments continue to be approved at a rapid pace, published findings suggest that oncologists, who are reputed to be slow to change, can quickly adjust practice based on post-approval safety data or when novel cancer therapies enter the market. Read more.

Access to care among ‘critical priorities’ for American Cancer Society’s new chief medical, scientific officer

William G. Cance, MD, has begun his new role as American Cancer Society’s chief medical and scientific officer. In an interview with HemOnc Today, Cance spoke about his priorities in his new role, the challenges he anticipates and how he hopes to meet them and his expectations for the oncology field in the coming years. Read more.